Filing Details

Accession Number:
0001127602-21-004257
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-05 20:06:48
Reporting Period:
2021-02-04
Accepted Time:
2021-02-05 20:06:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
318154 Amgen Inc AMGN Biological Products, (No Disgnostic Substances) (2836) 953540776
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1365306 P Jonathan Graham One Amgen Center Drive
Thousand Oaks CA 91320-1799
Evp, Gen. Counsel & Secy. No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-02-04 11,110 $236.51 39,945 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. The price reported is an average price. Full information regarding the number of shares sold at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer.
  2. These shares include the following RSUs granted under the Company's equity plans: 1,046 which will vest on 5/1/2021; 2,114 RSUs which vest in one installment of 1,041 on 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023; and 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
  3. These shares include 838 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.